Dr Lal PathLabs Limited on Friday reported its financial results for the third quarter of FY26, posting a year-on-year rise in revenue while net profit declined during the period.
Shares of Dr Lal PathLabs were trading at Rs 1399.90, up 0.35 per cent at 1:45 pm after the company announced the results.
Revenue from operations increased 10.6 per cent to Rs 6,598 crore in Q3 FY26 compared with Rs 5,967 crore in the corresponding quarter of the previous financial year. As a result, net profit declined 6.4 per cent to Rs 905 crore in Q3 FY26 from Rs 967 crore in the same quarter last year.
Total income for the quarter rose 10 per cent to Rs 6,842 crore from Rs 6,218 crore a year earlier. Total expenses increased 9.6 per cent to Rs 5,298 crore in the quarter under review, compared with Rs 4,835 crore in the year-ago period.
The company said EBITDA before exceptional items rose 16.3 per cent year-on-year during the quarter, supported by revenue growth. EBITDA margin before exceptional items stood at 27.2 per cent in Q3 FY26, compared with 25.8 per cent in the year-ago period. However, the profit and loss account for the quarter included an exceptional impact of Rs 30.1 crore on account of labour codes.
After factoring in the exceptional item, EBITDA for Q3 FY26 declined 3.2 per cent year-on-year. Profit before tax fell 10.1 per cent during the quarter, while profit after tax stood at Rs 91 crore, with a margin of 13.9 per cent. Earnings per share for the quarter declined to Rs 5.4 from Rs 5.8 in Q3 FY25.
Dr Lal PathLabs Nine-Month Results
For the first nine months of FY26, the company reported a 10.8 per cent rise in revenue to Rs 2,060 crore, compared with Rs 1,859 crore in the corresponding period of the previous year. EBITDA before exceptional items for the nine months increased 13.1 per cent, with margins improving to 28.9 per cent. EBITDA for the nine months rose 7.4 per cent to Rs 566 crore.
Profit before tax for the nine months ended December 2025 rose 8 per cent to Rs 509 crore, while net profit increased 12.2 per cent to Rs 378 crore compared with Rs 337 crore in the year-ago period. Earnings per share for the nine months stood at Rs 22.4 against Rs 20.0 a year earlier.
Dr Lal PathLabs Dividend
Dr Lal PathLabs also announced the declaration of its third interim dividend for FY26 at Rs 3.50 per equity share, representing 35 per cent on a face value of Rs 10 each.
Dr Lal PathLabs Dividend Record Date
The record date for payment of the interim dividend has been fixed as February 5, 2026. The company said the dividend will be credited to eligible shareholders within 30 days of its declaration.
Dr Lal PathLabs ESOP
During the quarter, the company also allotted 4,000 equity shares under its Employee Stock Option Plan 2010. Following the allotment, the paid-up equity share capital increased to Rs 1,67,55,50,200, comprising 16,75,55,020 equity shares of Rs 10 each.
Dr Lal PathLabs said its cash and bank balances stood at Rs 1,411 crore as on December 31, 2025.
Dr Lal PathLabs Company Profile
Dr Lal PathLabs Limited is a provider of diagnostic and related healthcare tests and services in India. The company operates through an integrated nationwide network offering a broad range of diagnostic services for patient diagnosis, prevention, monitoring, and treatment of diseases and health conditions.
As of March 31, 2025, the company had 298 clinical laboratories, including a National Reference Laboratory in Delhi and Regional Reference Laboratories in Kolkata, Bengaluru, and Mumbai. It also operated 6,607 patient service centres and 12,365 pick-up points across the country. Its customer base includes individual patients, hospitals, healthcare providers, and corporate clients.
Doonited Affiliated: Syndicate News Hunt
This report has been published as part of an auto-generated syndicated wire feed. Except for the headline, the content has not been modified or edited by Doonited
